PepGen Inc. (PEPG) |
|
10.46 -0.21 (-1.97%)
|
08-18 06:13 |
|
Open: |
10.51 |
Pre. Close: |
10.67 |
|
High:
|
11.98 |
Low:
|
10.12 |
|
Volume:
|
24,547 |
Market Cap:
|
247(M) |
|
|
|
|
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.99 - 12.06 |
12.06 - 12.12 |
|
Low:
|
9.98 - 10.05 |
10.05 - 10.11 |
|
Close:
|
10.36 - 10.47 |
10.47 - 10.57 |
|
Technical analysis |
as of: 2022-08-17 4:25:49 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 13.5 One year: 15.25 |
| Support: |
Support1: 9.14 Support2: 7.61 |
| Resistance: |
Resistance1: 11.56 Resistance2: 13.06 |
| Pivot: |
11.11 |
| Moving Average: |
MA(5): 10.68 MA(20): 11.4
MA(100): 0 MA(250): 0 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 19.7  %D(3): 20.9 |
| RSI: |
RSI(14): 44.5 |
| 52-week: |
High: 13.06 Low: 7.82 |
| Average Vol(K): |
3-Month: 94 (K) 10-Days: 19 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PEPG ] has closed above bottom band by 19.9%. Bollinger Bands are 0% narrower than normal. |
|
|
Headline News |
Tue, 16 Aug 2022
What is the Market's View on PepGen Inc (PEPG) Stock's Price and Volume Trends Tuesday? - InvestorsObserver
Tue, 16 Aug 2022
Partisan Rifts Widen, Perceptions of School Quality Decline - EducationNext
Tue, 16 Aug 2022
Parental Anxieties over Student Learning Dissipate as Schools Relax Anti-Covid Measures - EducationNext
Fri, 12 Aug 2022
2022-08-12 | NDAQ:PEPG | Press Release | PepGen Inc. - Stockhouse
Wed, 10 Aug 2022
PepGen (NASDAQ:PEPG) Shares Down 9.3% - Defense World
Sun, 07 Aug 2022
Agenda set for RSU 71 board meeting Aug. 8 - PenBayPilot.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
24 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
32 (%) |
|
% Held by Institutions
|
54.9 (%) |
|
Shares Short
|
292 (K) |
|
Shares Short P.Month
|
9 (K) |
Stock Financials |
|
EPS
|
-42.35 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-51.46 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
-62 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.45 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-32 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.25 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.21 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-7.72 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
